8-K: Replimune Reports Q2 2026 Results, RP1 FDA Review Advances

Replimune Group, Inc. announced its fiscal second quarter 2026 financial results and provided an update on its clinical programs, including the FDA's acceptance of the BLA resubmission for RP1 with a PDUFA date of April 10, 2026.

Summary

• The FDA accepted the Biologics License Application (BLA) resubmission for RP1 for the treatment of advanced melanoma, setting a Prescription Drug User Fee Act (PDUFA) target action date for April 10, 2026.
• The FDA indicated that the IGNYTE-3 trial could potentially support approval for RP1.
• Net loss for the fiscal second quarter ended September 30, 2025, was $83.1 million, an increase from $53.1 million for the same period in 2024.
• Cash, cash equivalents, and short-term investments totaled $323.6 million as of September 30, 2025, down from $483.8 million as of March 31, 2025.
• Research and development expenses increased to $57.9 million for Q2 2026 from $43.4 million for Q2 2025, driven by RP1 direct research costs and RP2 study costs.
• Selling, general and administrative expenses rose to $26.4 million for Q2 2026 from $15.5 million for Q2 2025, partly due to preparations for a potential RP1 commercial launch.
• The company believes existing cash will fund operations late into the fourth quarter of 2026.
• Positive acral melanoma data for RP1 plus nivolumab from the IGNYTE trial showed an objective response rate (ORR) of 44% (8/18) with a median duration of response of 11.9 months.
• RP1 plus nivolumab also demonstrated responses across multiple advanced non-melanoma skin cancer (NMSC) tumor types, with ORRs ranging from 100% in anti-PD-1 naive MCC to 15.2% in anti-PD-1 failed CSCC.
• Enrollment is ongoing for the global Phase 3 IGNYTE-3 trial for RP1 in advanced melanoma and the registration-directed Phase 2/3 REVEAL trial of RP2 in metastatic uveal melanoma.
• A Phase 2 trial of RP2 in hepatocellular carcinoma is enrolling, with data planned by the end of 2026, and a new RP2 cohort for biliary tract cancer is expected to enroll its first patient in Q4 2025.
• Replimune will present updated clinical and biomarker data for RP1 at the Society for Immunotherapy of Cancer (SITC) 2025 40th Annual Meeting.

Sentiment

Score: 6

Explanation: The acceptance of the BLA resubmission for RP1 and positive clinical data in various skin cancers are significant positive developments, indicating progress towards commercialization and pipeline strength. However, the substantial increase in net loss and cash burn, while expected for a clinical-stage biotech, temper the overall sentiment, reflecting the financial challenges of drug development.

Positives

• The FDA accepted the BLA resubmission for RP1 in advanced melanoma, setting a PDUFA target action date of April 10, 2026, indicating significant progress towards potential market approval.
• The FDA's indication that the IGNYTE-3 trial could potentially support approval is a positive signal for the ongoing Phase 3 study.
• RP1 plus nivolumab demonstrated a 44% objective response rate (ORR) and a median duration of response of 11.9 months in acral melanoma patients who had failed anti-PD-1 therapy, highlighting efficacy in a difficult-to-treat population.
• RP1 plus nivolumab showed promising responses across various advanced non-melanoma skin cancer (NMSC) tumor types, including high ORRs in anti-PD-1 naive MCC (100%), angiosarcoma (66.7%), and CSCC (56.3%).
• The company maintains a robust clinical pipeline with ongoing Phase 3 trials for RP1 and Phase 2/3 trials for RP2 across multiple cancer indications.
• Existing cash, cash equivalents, and short-term investments of $323.6 million are projected to fund operations late into the fourth quarter of 2026, providing financial runway.

Negatives

• Net loss significantly increased to $83.1 million for the fiscal second quarter ended September 30, 2025, compared to $53.1 million for the same period in the prior year.
• Cash, cash equivalents, and short-term investments decreased by $160.2 million, from $483.8 million as of March 31, 2025, to $323.6 million as of September 30, 2025, reflecting a high cash burn rate.
• Research and development expenses increased by $14.5 million to $57.9 million for Q2 2026, indicating rising costs associated with advancing clinical programs.
• Selling, general and administrative expenses increased by $10.9 million to $26.4 million for Q2 2026, partly due to increased personnel-related costs for potential commercial launch preparation.
• The company previously received a complete response letter (CRL) on July 21, 2025, for RP1, which represented a setback in the initial approval timeline, although the resubmission has now been accepted.

Risks

• Limited operating history.
• Ability to generate positive clinical trial results for product candidates.
• Costs and timing of operating the in-house manufacturing facility.
• Timing and scope of regulatory approvals.
• Availability of combination therapies needed to conduct clinical trials.
• Changes in laws and regulations to which the company is subject.
• Competitive pressures in the biotechnology and oncology markets.
• Ability to identify additional product candidates.
• Political and global macro factors, including the impact of global pandemics and related public health issues, and ongoing political and military conflicts, including trade conflicts.

Future Outlook

The company anticipates potential FDA approval for RP1 in advanced melanoma by April 10, 2026, and expects to fund operations late into the fourth quarter of 2026 with existing cash. They plan to publish ARTACUS trial data in 2026 and release RP2 monotherapy data in hepatocellular carcinoma by the end of 2026, with a new RP2 cohort in biliary tract cancer starting enrollment in Q4 2025.

Management Comments

• "After a collaborative dialogue and productive engagement with the FDA we are encouraged by the acceptance of our BLA resubmission for RP1 in combination with nivolumab."
• "We are currently partnering with the agency on the ongoing review to bring this important therapy to patients."

Industry Context

Replimune operates in the highly competitive and innovative field of oncolytic immunotherapies, a growing area within cancer treatment. The focus on advanced melanoma, non-melanoma skin cancers, uveal melanoma, hepatocellular carcinoma, and biliary tract cancer addresses significant unmet medical needs. The combination of oncolytic viruses with checkpoint inhibitors like nivolumab (a standard of care in many cancers) is a common strategy to enhance anti-tumor immune responses, aligning with broader industry trends towards combination therapies and personalized medicine. The positive clinical data for RP1 in various skin cancers, including those that have failed prior anti-PD-1 therapy, positions Replimune as a potential innovator in these difficult-to-treat populations.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or global benchmarks.
• The objective response rate (ORR) of 44% for RP1 plus nivolumab in acral melanoma patients who failed anti-PD-1 therapy is a notable result, as this patient population typically has limited treatment options and poor prognoses, suggesting potential competitiveness in this niche.
• The high ORRs observed in anti-PD-1 naive non-melanoma skin cancers (e.g., 100% in MCC) suggest strong potential, though these are from ongoing trials and not direct comparisons to approved therapies.

Stakeholder Impact

• Shareholders: Potential for increased value if RP1 receives FDA approval, but continued high cash burn and net losses pose financial risk. Clinical progress and FDA acceptance provide positive momentum.
• Patients: Potential new treatment option (RP1) for advanced melanoma and other skin cancers, offering hope for improved outcomes, especially for those who have failed previous therapies.
• Employees: Continued investment in R&D and commercialization preparation suggests job stability and growth opportunities, particularly in clinical development and potential commercial roles.
• Regulatory Authorities (FDA): Ongoing collaborative engagement with the FDA for RP1 review, indicating a constructive relationship.

Next Steps

• Ongoing FDA review of RP1 BLA resubmission with a PDUFA target action date of April 10, 2026.
• Continue enrollment for the global Phase 3 IGNYTE-3 trial for RP1 in advanced melanoma.
• Continue enrollment for the registration-directed Phase 2/3 REVEAL trial of RP2 in metastatic uveal melanoma.
• Continue enrollment for the Phase 2 clinical trial of RP2 in hepatocellular carcinoma, with a protocol amendment to include RP2 monotherapy and data planned by the end of 2026.
• Enroll the first patient in the RP2 biliary tract cancer cohort in Q4 2025.
• Present biomarker and updated clinical data for RP1 at SITC 2025 (November 7th).
• Present subgroup analysis data for RP1 at SITC 2025 (November 7th).
• Present retreatment data for RP1 at SITC 2025 (November 8th).
• Planned publication for ARTACUS trial data in 2026.

Key Dates

Recommendation

While the FDA's acceptance of the BLA resubmission for RP1 and the positive clinical data are strong catalysts, indicating significant progress towards potential market entry, the company's substantial cash burn and increasing net losses warrant caution. The cash runway extends only into late Q4 2026, suggesting a potential need for future financing if commercialization revenues are not substantial or timely. Investors should hold to monitor the FDA's decision on RP1 by April 2026 and the progress of other pipeline assets, balancing the significant upside potential with the inherent financial risks of a clinical-stage biotechnology company.

Keywords

oncolytic immunotherapy, advanced melanoma, RP1, vusolimogene oderparepvec, RP2, nivolumab, anti-PD-1, anti-CTLA-4, non-melanoma skin cancer, NMSC, uveal melanoma, hepatocellular carcinoma, biliary tract cancer, FDA BLA, PDUFA, biotechnology, clinical stage, cancer treatment, immunotherapy, HSV-1 backbone, IGNYTE-3, REVEAL, ARTACUS